224 related articles for article (PubMed ID: 19178153)
41. Discovery of 3-acetyl-4-hydroxy-2-pyranone derivatives and their difluoridoborate complexes as a novel class of HIV-1 integrase inhibitors.
Ramkumar K; Tambov KV; Gundla R; Manaev AV; Yarovenko V; Traven VF; Neamati N
Bioorg Med Chem; 2008 Oct; 16(19):8988-98. PubMed ID: 18805696
[TBL] [Abstract][Full Text] [Related]
42. Integrase inhibitors for the treatment of HIV infection.
Pace P; Rowley M
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):471-9. PubMed ID: 18600564
[TBL] [Abstract][Full Text] [Related]
43. The design of 8-hydroxyquinoline tetracyclic lactams as HIV-1 integrase strand transfer inhibitors.
Velthuisen EJ; Johns BA; Temelkoff DP; Brown KW; Danehower SC
Eur J Med Chem; 2016 Jul; 117():99-112. PubMed ID: 27092410
[TBL] [Abstract][Full Text] [Related]
44. HIV type 1 integrase inhibitors: from basic research to clinical implications.
Jegede O; Babu J; Di Santo R; McColl DJ; Weber J; Quiñones-Mateu M
AIDS Rev; 2008; 10(3):172-89. PubMed ID: 18820719
[TBL] [Abstract][Full Text] [Related]
45. Discovery and synthesis of HIV integrase inhibitors: development of potent and orally bioavailable N-methyl pyrimidones.
Gardelli C; Nizi E; Muraglia E; Crescenzi B; Ferrara M; Orvieto F; Pace P; Pescatore G; Poma M; Ferreira Mdel R; Scarpelli R; Homnick CF; Ikemoto N; Alfieri A; Verdirame M; Bonelli F; Paz OG; Taliani M; Monteagudo E; Pesci S; Laufer R; Felock P; Stillmock KA; Hazuda D; Rowley M; Summa V
J Med Chem; 2007 Oct; 50(20):4953-75. PubMed ID: 17824681
[TBL] [Abstract][Full Text] [Related]
46. Discovery of potent HIV integrase inhibitors active against raltegravir resistant viruses.
Le G; Vandegraaff N; Rhodes DI; Jones ED; Coates JA; Lu L; Li X; Yu C; Feng X; Deadman JJ
Bioorg Med Chem Lett; 2010 Sep; 20(17):5013-8. PubMed ID: 20685117
[TBL] [Abstract][Full Text] [Related]
47. Mining the NCI antiviral compounds for HIV-1 integrase inhibitors.
Deng J; Kelley JA; Barchi JJ; Sanchez T; Dayam R; Pommier Y; Neamati N
Bioorg Med Chem; 2006 Jun; 14(11):3785-92. PubMed ID: 16460953
[TBL] [Abstract][Full Text] [Related]
48. Single amino acid substitution in HIV-1 integrase catalytic core causes a dramatic shift in inhibitor selectivity.
Al-Mawsawi LQ; Sechi M; Neamati N
FEBS Lett; 2007 Mar; 581(6):1151-6. PubMed ID: 17328897
[TBL] [Abstract][Full Text] [Related]
49. Discovery and structure-activity relationship studies of a unique class of HIV-1 integrase inhibitors.
Dayam R; Sanchez T; Neamati N
ChemMedChem; 2006 Feb; 1(2):238-44. PubMed ID: 16892356
[TBL] [Abstract][Full Text] [Related]
50. Lack of integrase inhibitors associated resistance mutations among HIV-1C isolates.
Mulu A; Maier M; Liebert UG
J Transl Med; 2015 Dec; 13():377. PubMed ID: 26626277
[TBL] [Abstract][Full Text] [Related]
51. The terminal (catalytic) adenosine of the HIV LTR controls the kinetics of binding and dissociation of HIV integrase strand transfer inhibitors.
Langley DR; Samanta HK; Lin Z; Walker MA; Krystal MR; Dicker IB
Biochemistry; 2008 Dec; 47(51):13481-8. PubMed ID: 18991395
[TBL] [Abstract][Full Text] [Related]
52. Naphthoxazepine inhibitors of HIV-1 integrase: synthesis and biological evaluation.
Garofalo A; Grande F; Brizzi A; Aiello F; Dayam R; Neamati N
ChemMedChem; 2008 Jun; 3(6):986-90. PubMed ID: 18383063
[TBL] [Abstract][Full Text] [Related]
53. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
Summa V; Petrocchi A; Bonelli F; Crescenzi B; Donghi M; Ferrara M; Fiore F; Gardelli C; Gonzalez Paz O; Hazuda DJ; Jones P; Kinzel O; Laufer R; Monteagudo E; Muraglia E; Nizi E; Orvieto F; Pace P; Pescatore G; Scarpelli R; Stillmock K; Witmer MV; Rowley M
J Med Chem; 2008 Sep; 51(18):5843-55. PubMed ID: 18763751
[TBL] [Abstract][Full Text] [Related]
54. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients.
Malet I; Delelis O; Soulie C; Wirden M; Tchertanov L; Mottaz P; Peytavin G; Katlama C; Mouscadet JF; Calvez V; Marcelin AG
J Antimicrob Chemother; 2009 Apr; 63(4):795-804. PubMed ID: 19221102
[TBL] [Abstract][Full Text] [Related]
55. Pharmacophore development and docking studies of the hiv-1 integrase inhibitors derived from N-methylpyrimidones, Dihydroxypyrimidines, and bicyclic pyrimidinones.
Telvekar VN; Patel KN
Chem Biol Drug Des; 2011 Jul; 78(1):150-60. PubMed ID: 21518263
[TBL] [Abstract][Full Text] [Related]
56. Investigations on the 4-quinolone-3-carboxylic acid motif. 1. Synthesis and structure-activity relationship of a class of human immunodeficiency virus type 1 integrase inhibitors.
Pasquini S; Mugnaini C; Tintori C; Botta M; Trejos A; Arvela RK; Larhed M; Witvrouw M; Michiels M; Christ F; Debyser Z; Corelli F
J Med Chem; 2008 Aug; 51(16):5125-9. PubMed ID: 18665580
[TBL] [Abstract][Full Text] [Related]
57. Symmetrical 1-pyrrolidineacetamide showing anti-HIV activity through a new binding site on HIV-1 integrase.
Du L; Zhao YX; Yang LM; Zheng YT; Tang Y; Shen X; Jiang HL
Acta Pharmacol Sin; 2008 Oct; 29(10):1261-7. PubMed ID: 18817633
[TBL] [Abstract][Full Text] [Related]
58. [Analysis of HIV-1 integrase gene polymorphism in an HIV-infected population from the nosocomial outbreak of HIV infection in the south of Russia in 1989].
Gafarova IE; Shideeva ZhA; Sandzhieva DB; Garaev MM
Vopr Virusol; 2010; 55(1):16-22. PubMed ID: 20364666
[TBL] [Abstract][Full Text] [Related]
59. Design, synthesis, and biological evaluation of novel tricyclic HIV-1 integrase inhibitors by modification of its pyridine ring.
Metobo SE; Jin H; Tsiang M; Kim CU
Bioorg Med Chem Lett; 2006 Aug; 16(15):3985-8. PubMed ID: 16723226
[TBL] [Abstract][Full Text] [Related]
60. Azaindole hydroxamic acids are potent HIV-1 integrase inhibitors.
Plewe MB; Butler SL; Dress KR; Hu Q; Johnson TW; Kuehler JE; Kuki A; Lam H; Liu W; Nowlin D; Peng Q; Rahavendran SV; Tanis SP; Tran KT; Wang H; Yang A; Zhang J
J Med Chem; 2009 Nov; 52(22):7211-9. PubMed ID: 19873974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
